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ABSTRACT 
Arginine-vasopressin (AVP) and its associated neurophysin (AVP-NP) are 
synthesized via a precursor, propressophysin, which also contains a 39 amino 
acid glycopeptide at its C-terminus (C-terminus of propressophysin, or CPP). 
In the present study, immunocytochemical techniques were used to determine the 
cellular co-localization of CPP with AVP, oxytocin (OXY), AVP-NP and OXY-NP in 
the rat hypothalamus using colchicine pre-treatment and serial 5 urn section 
analysis. Extensive cross-competition studies of antisera raised against each 
peptide with the various antigens yielded no significant crossreactivity of 
the CPP, AVP, OXY and NP antisera. The NP antiserum, although directed 
against both AVP-NP and OXY-NP, demonstrated a preference for OXY-NP at a 
dilution of 1:20,000. CPP and AVP were always co-localized within the same 
magnocellular neurons of the supraoptic, paraventricular and circularis 
nuclei, and further showed very similar patterning in the suprachiasmatic 
nucleus as well. In conrast, no cellular overlap could be detected between 
CPP and OXY, in any of the above nuclei (the suprachiasmatic nucleus is devoid 
of OXY). Likewise, no examples of co-localization of CPP and OXY-NP were 
found in the magnocellular nuclei. These results are in strong agreement with 
a biosynthetic relationship between CPP, AVP and AVP-NP, and their 
separateness from the OXY and OXY-NP precursor. 
INTRODUCTION 
A 39 amino acid glycopeptide extracted from pituitary has been sequenced 
by three separate laboratories over the last few years (l-3). Based on its 
size, source and distribution, Seidah et al. (1) suggested it to be part of 
the vasopressin precursor. This peptide is highly conserved in four species: 
human, pig, sheep and ox. Recently the cDNA structure of the mRNA for the 
precursor to arginine-vasopressin (AVP) and its associated neurophysin 
(AVP-NP) have been sequenced (4). The general structure of that mRNA involves 
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coding for a signal sequence, followed by AVP, then NP, and finally as 
expected (1) the 39 amino acid glycopeptide described above, namely the 
C-terminal peptide of propressophysin (CPP). Using antisera directed against 
this C-terminal 39 amino acid glycopeptide, we had previously shown that the 
peptide is uniquely localized in the posterior lobe of pituitary, the internal 
layer of the median eminance, and in the magnocellular neurosecretory neurons 
of rat hypothalamus, and is absent in several magnocellular nuclei of the 
homozygous Brattleboro rat (a strain known not to contain AVP or AVP-NP) 
(5,6). Specifically, a subset of neurons within the supraoptic, 
paraventricular and circularis nuclei have been stained by the specific CPP 
antiserum, with fibers leading from these neurons into the internal layer of 
the median eminance. Further, upon analysis of the parvocellular component of 
the suprachiasmatic nucleus, which does not contain oxytocin (OXY) cell 
bodies, many small perikarya were detected with the C-terminal peptide 
antiserum. Using specific AVP antisera, we were able to demonstrate the 
co-localization of CPP and AVP in the supraoptic and paraventricular nuclei 
(5). Thus, several lines of evidence suggested an intimate relationship 
between CPP and AVP. 
In this paper we report on an immunocytochemical study of the cellular 
localization of CPP-like immunoreactivity as compared to AVP, OXY and 
OXY-associated NP (OXY-NP), in several hypothalamic magnocellular and 
parvocellular nuclei. The results of this study strongly support the 
biosynthetic relationship between CPP, AVP, and AVP-NP, but do not support a 
relationship between CPP and OXY. 
MATERIALS AND METHODS 
CPP was extracted as reported elsewhere (1). The peptide was conjugated 
via carbodiimide to ovalbumin, and injected in multiple subcutaneous sites on 
the back of rabbits. The serum harvested was used for immunocytochemical 
study at a titer of approximately 1:lOOO in the immunocytochemical paradigm 
reported elsewhere (5). Under the immunocytochemical conditions studied, the 
binding of CPP to the CPP antiserum was not blocked by up to 50,M 
concentrations of AVP, OXY, a combination of OXY-NP and AVP-NP, B-endorphin, 
c-MSH, [Met]- and [Leulenkephalin. or dynorphin A. It could be blocked by as 
little as 10 nM concentration of CPP itself. 
AVP and OXY antisera (from EZ and GN; and TvWG) were produced by linking 
their respective peptides via carbodiimide to thyroglobulin for rabbit 
immunization. The resulting antisera were used in immunocytochemical titer of 
1:lOOO. The binding of AVP to AVP antisera could not be blocked by OXY, CPP, 
OXY-NP and AVP-NP, [Met]- and [Leulenkephalin, dynorphin A, g-endorphin, ACTH 
or c-MSH in concentrations up to 50 p M. However, AVP could block the 
immunocytochemical demonstration by AVP antiserum in concentrations as low as 
100 nM. Similar characterization for the OXY antibodies was obtained. AVP , 
CPP, OXY-NP, AVP-NP, [Met]- and Leulenkephalin, dynorphin, g-endorphin, ACTH, 
or c-MSH were unable to block the binding of OXY to OXY antisera at 
concentrations up to 50 uM. However, OXY antibodies could be blocked by OXY 
itself at approximately 100 nM concentration. 
The NP antiserum used in this study (Robinson 14) is directed to both rat 
neurophysins, and has been previously characterized (7). It was used at 
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immunocytochemical titer of 1:20,000. None of the peptides listed above could 
block the binding of NP to its antiserum at concentrations of up to 5011 M, 
with the exception of a mixture of rat neurophysins (a generous gift of 
J. Russell and H. Gainer, NIH) at 1 nM. Although directed against both 
neurophysins, at a dilution of 1:20,000 the antiserum generally stained OXY 
cells and was therefore assumed to be largely directed against OXY-NP. 
Five animals were prepared from each of the following groups: normal and 
colchicine pretreated Sprague-Dawley male rats. Colchicine pretreatment was 
carried out 48 hours prior to sacrifice by the ICV administration of 501.1 g of 
colchicine in 50~ 1 of normal saline under ether anesthesia. All animals were 
perfused via the ascending aorta with cold neutral-buffered 4% formaldehyde 
and prepared for immunocytochemistry as described elsewhere (8). Brains from 
all animals were sectioned in the frontal plane through the supraoptic, 
paraventricular, circularius, and suprachiasmatic nuclei. The tissue was 
prepared for immunohistochemistry using the concentrations of primary 
antiserum described above. The PAP technique as described by Sternberger (9) 
was modified for tissue staining (10). All the blocking studies were carried 
out in the presence of up to 50~ M peptide. 
The specific staining paradigm involved the use of serial 5 pm frozen 
sections in groups of twelve. Sections 1 and 12 were used for the peptide 
blocking control for the two peptides to be studied (e.g., AVP and CPP). The 
remaining sections (2-11) were stained alternately for each of the peptides. 
For example, sections 2,4,6,8, and 10 were stained for CPP ) whereas 3,5,7,9 
and 11 were stained for AVP. The goal of this paradigm was the attempted 
co-localization of the two peptides within the same cell. For a particular 
cell to be seen as positively stained for both peptides, it must occur in at 
least three consecutive sections and be clearly stained by both antisera. 
Because of the size of individual magnocellular neurons, any one cell often 
occurs in two, three or more serial 5~ m sections. Comparisons were carried 
out for sera against the following peptides: AVP versus CPP, OXY versus CPP, 
NP versus CPP, and NP versus AVP. Sections through the supraoptic nucleus, 
paraventricular nucleus, nucleus circularis, and suprachiasmatic nucleus were 
taken for the study of these several staining comparisons. 
RESULTS 
CPP and AVP were seen to stain similar regions of the supraoptic, 
paraventricular and circularis nuclei. Upon careful analysis of serial 
sections prepared as described above, it became clear that CPP and AVP 
immunoreactivities are localized to the same cells within the supraoptic 
nucleus (Fig. 11, paraventricular nucleus (Fig. 2), and nucleus circularis 
(Fig. 3). Because of the small size of the cells in the suprachismatic 
nucleus, it was not possible to co-localize the two peptides. However, it 
should be noted that there are no OXY staining cells in that nucleus (see 
Figure 4) and that the pattern of staining using CPP and AVP antisera is very 
similar. 
Within the limits of the resolution of this type of serial section 
analysis, no examples could be detected of CPP or AVP staining independent of 
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Figure 1. Supraoptic nucleus: 
AVP and CPP immunoreactivity. 
This nucleus has cells which contain both 
sections 
colchicine pretreated 
Serial 5 in m were taken from a 
rat (50 ug ICV, 48 hours prior to sacrifice). Sections 
were stained with antiserum against CPP (panel A) or AVP (panel B). 
cells, stained with both sera, 
Many 
numbered cells). 
can be identified in both sections (see 
bar equals 20 urn. 
Star is in a common vessel. OT: optic tract. Calibration 
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Figure 2. Paraventricular nucleus: This nucleus has cells which contain 
both AVP and CPP immunoreactivity. The same animal and methods were used as 
in Figure 1. Panel B shows cells stained with anti-AVP serum, whereas panels 
A and C were stained with anti-CPP serum. Commonly stained cells are numbered 




Figure 3. Nucleus 
circularis: This nucleus has 
cells which contain both AVP 
and CPP immunoreactivity. The 
same animal and methods were 
used as ih Figure 1. Panel B 
shows cells stained with 
anti-CPP serum, whereas panels 
A and C show cells stained 
with anti-AVP serum. Commonly 
stained cells are numbered in 
all three panels. Star is in 
a common vessel. Calibration 




Figure 4. Suprachiasmatic nucleus: Cells of this nucleus contain CPP 
but not OXY immunoreactivity. The same animal and methods were used as in 
Figure 1. Arrows indicate two of the many CPP-stained cells. The inset photo 
is from an adjacent section and was exposed to anti-OXY serum. NO 
OXY-positive cells appeared in this nucleus, whereas cells in other areas of 
the same animal were OXY-positive. Star is in a common vessel. Calibration 
bar equals 20 ,, m. 
the other. However, it should be noted that analysis of serial 5~ m sections 
cannot eliminate the possibility of two immunoreactive peptides occuring 
independently in separate cells. This type of analysis is conservative and 
can only provide evidence that two given immunoreactive substances occur in 
some or most cells of a particular region. Given these considerations, we 
conclude that CPP and AVP immunoreactivities are stored together extremely 
commonly, but cannot yet exclude the possibility of occasional separate 
localization. 
The relationship between CPP and OXY is characterized in figures 5 
through 7. The same nuclei, supraoptic (Fig. 5). paraventricular (Fig. 6) and 
circularis (Fig. 71, all contain OXY positive cells, but in no case were we 
able to detect cellular overlap between CPP and OXY. In all these cases, we 
were able to detect cells which had been stained with CPP but which were 
unstained in the adjacent section by OXY. The suprachiasmatic nucleus as 
reported above was unstained by OXY, yet was stained by CPP (Fig. 4). While 
it is very difficult to eliminate the possibility of two substances being 
co-stored in the same cells under the conditions used here. no example of OXY 
or dPP-like immunoreactivity within the same cells could be detected. 
327 
Figure 5. Supraoptic nucleus: 
OXY-positive cells do not stain with 
CPP antiserum. Serial 511 m sections 
were taken from a colchicine 
pretreated rat (50, g ICV, 48 hours 
prior to sacrifice). Anti-OXY serum 
was used to stain cells in panels A 
and C, whereas anti-CPP serum 
stained cells in panel B. Note that 
OXY-positive cells are sparsely and 
widely distributed at this level of 
the nucleus. In contrast, 
CPP-containing cells are 
predominantly located in the ventral 
portion of the nucleus (see dotted 
line). Single arrow in panels A and 
C shows an OXY-positive cell which 
is not seen in CPP-stained tissue in 
panel B (double arrow). Calibration 
bar equals 20, m. 
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Figure 6. Paraventricu- 
lar nucleus: OXY-positive 
cells do not stain with CPP 
antiserum. The same animal 
and methods were used as in 
Figure 4. Anti-OXY serum was 
used to stain cells in panels 
A and C, whereas anti-CPP 
serum stained cells in panel 
B. Note that OXY-positive 
cells are more plentiful than 
CPP-positive cells. The 
single arrow in panels A and C 
and double-arrow in panel B 
point to the same cell, which 
is unstained with OXY 
antiserum, but is stained with 
CPP antiserum. Star is in a 
common vessel. Calibration 
bar equals 20, m. 
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Figure 7. Nucleus circularis: OXY-positive cells do not stain with 
anti-CPP serum. The same animal and methods were used as in Figure 4. 
Anti-OXY (panel B) and anti-CPP (panel A) stain different cells. For example, 
note that cell number 1 (double arrow) is OXY-stained but not CPP-stained 
(single arrow), whereas cell number 2 (single arrow) is CPP-stained but not 
OXY-stained (double arrow). Star is in common vessel. Calibration bar equals 
20 Um. 
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Figure 8. Nucleus circularis: The NP antiserum used in this study 
preferentially stains OXY cells and generally does not stain CPP cells. Cells 
in panels A and C were stained with the anti-NP serum, while cells in panel B 
were stained with anti-OXY serum; cells in panel D were stained with anti-CPP 
serum. Note that NP (panel A) and OXY (panel B) stain the same cells (see 
numbered cells in both panels). In contrast, a large number of CPP-stained 
cells (panel D) are unstained (or very lightly stained) by the anti-NP (panel 
C). The two cells (arrows) that are stained by both NP and CPP antisera, 
probably contain AVP-NP and are vasopressinergic. It is assumed that the 
staining of some AVP cells by the NP antiserum is a'result of crossreactivity 
between both AVP-NP and OXY-NP. Stars indicate a common vessel in panels A, 
B. and panels C, D. Calibration bar equals 20 urn. 
**** 
The NP antiserum used in this study seems to contain antibodies against 
both OXY-NP and AVP-NP. At 1:20,000 dilution, all OXY-containing cells were 
stained with the NP antiserum (Fig. 8A, B). However, under the same 
conditions, and in the same animals, it was shown that CPP and OXY-NP appear 
not to co-localize to the same magnocellular neurons of supraoptic, 
paraventricular, and circularis nuclei (Fig. 8C, D). In general the NP 
antiserum tended not to stain the CPP positive cells, with few exceptions (see 
arrows Fig. 8C, D). We are unable to be more certain about this point because 
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Figure 9. Paraventricular nucleus: Neither OXY nor AVP-stained cells 
are blocked by NP, but are blocked by OXY and AVP, respectively. As reported 
in the text, OXY antiserum was not blocked by AVP, and AVP antiserum was not 
blocked by OXY. Cells in panels A, B and C were stained with OXY antiserum. 
Cells in panel B were also exposed to 50 1-1 M NP (a mixture of OXY-NP and 
AVP-NP), while cells in panel C were exposed to 10, M OXY. Note the complete 
blockade of staining with OXY. Star is in a common vessel in A, B, and C. 
Cells in panels D, E, and F were stained with AVP antiserum. Cells in panel E 
were exposed to 50 uM NP, and cells in panel F to 10 PM AVP. Note the 
blockade with AVP. Star is in a common vessel in D, E, and F. Calibration 
bar equals 20 pm. 
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Figure 10. Paraventricular nucleus: NP antiserum was not blocked by 
CPP, but was blocked by NP itself. In contrast, CPP antiserum was not blocked 
by NP, but by CPP itself. Cells in panels A, B, and C were stained with NP 
antiserum. Cells in panel B were exposed to 50~ M CPP. Cells in panel C were 
blocked by 1,M NP. Cells in panels D, E, and F were stained with CPP 
antiserum. Cells in panel E were exposed to 50~ M NP (OXY-NP and AVP-NP). 
Cells in panel F were blocked by 1~ M CPP. Star is in vessels common to A, B, 
C, and D, E, F. Calibration bar equals 20U m. 
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Cross-blocking studies between OXY and NP (Fig. qA, 3, C), AVP and NP 
(Fig. 9D, E, F), as well as NP and CPP (Fig. 10) yielded no examples of 
cross-reactivity between the several antisera and the peptides tested. Thus 
it is not reasonable to attribute CPP staining to cross-reactivity with NP or 
any other tested peptides. 
DISCUSSION 
The immunocytochemical analysis of the localization of the CPP-like im- 
munoreactivity is in very strong agreement with the distribution pattern of 
AVP in all the magnocellular nuclei of rat brain. Examples of co-localization 
of AVP and CPP in each of the hypothalamic nuclear areas have been presented. 
No examples of cellular co-localization of CPP immunoreactivity with OXY was 
detected, even though the same number of studies under blind conditions were 
carried out in parallel with CPP, AVP and OXY staining. It would appear that 
OXY has no clear relationship to CPP, and if OXY has a similarly constructed 
precursor which has yet to be proven, it may have a peptide at its C-terminus 
which has a different structure than CPP. 
The relationship between AVP, its associated AVP-NP and CPP (4) raises 
significant questions about the native biology of each of the three peptide 
products. The biology of AVP, while complex, is well studied. It has many 
effects across a variety of target systems and is, in its own right, a very 
potent substance (cf. 11-13). The role of NP has been studied somewhat less 
and has been thought to be that of a carrier protein (cf. 141, but could well 
be without any important biological function. No biological effects in the 
administration of NP have been reported. Because of the highly conservative 
nature of the C-terminal glycopeptide of propressophysin, it is interesting to 
speculate what role it might play. Is it a carrier protein, an active 
peptide, or does it perhaps play a role in modulating or synergizing with AVP 
or NP? An increasingly important principle emerging from neuropeptide 
research is that of co-synthesis of several bioactive substances from the same 
precursor. In the case of pro-opiomelanocortin, ACTH, ~1 -MSH, R-endorphin 
and a long N-terminal fragment are produced by the same precursor in endocrine 
and neuronal cells (15-19). Some groups have reported a synergistic effect in 
peripheral endocrine function and in central neural function of two or three 
peptides from the same pro-opiomelanocortin precursor (20-22). It is 
conceivable that a similar type of interaction might occur between AVP, NP and 
CPP . 
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